Loading...
Loading...
BCEL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 21.3M |
| Operating I/L | -22.7M |
| Other Income/Expense | 1.4M |
| Interest Income | 0.4M |
| Pretax | -21.3M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -20.9M |
Atreca, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based immunotherapeutics for solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a unique mechanism of action that targets a novel antigen. The company's product pipeline also includes APN-122597, a receptor tyrosine kinase targeting tumor tissues, and ATRC-501/MAM01, which targets the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Atreca has collaboration and licensing agreements with Xencor, Inc. and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of novel antibodies in oncology and malaria prevention, respectively.
